f'u:NARY:
`JoJNT SESSION
`
`Abstract# 428
`SIROLIMUS PREVENTS TUMOR PROGRESSION: mTOR
`TARGETING FOR THE INHIBITION OF NEOPLASTIC
`PROGRESSION. Fulung Luan, 1 Mary Maluccio,2 Vijay K. Sharma,'
`Minoru Hojo,' Milagros Lagman,' Manikkam Suthanthiran.'
`1Nephrology/Transplantation Medicine, New York Presbyterian
`Hospital, Weill Medical College of Cornell University, New York, NY;
`2Surgery. New York Presbyterian Hospital, Weill Medical College of
`Cornell University, New York, NY.
`Post-transplant malignancy i; a life-threatening complication. Immunosuppress1ve
`drug induced impairments in host-immune effector mechanisms are considered to be
`the prime mechamsms. This paradigm has been challenged by the report that
`cyclosporine (CSA) can promote tumor progression independent of its effect on
`the host immune cells and by a cell autonomous mechanism. The universality of
`this mechanism was investigated by explonng the effect of tacrolimus and s1rolimus
`on tumor progression. SCIO-beige mice that lack functional T-cells, B-cells and NK
`cells were used as the tumor bearing host, and a renal carcinoma was used as the tumor
`inoculum. The impact of these two immunosuppressants was diametrically opposite.
`Whereas tacrolimus (4 mg/kg, QOD, SQ) increased the number of pulmonary renal
`cancer metastases (p<O 05), Bonferroni p value), sirolimus (4 mg/kg, QOD,SQ)
`prevented pulmonary metastasis (p<0.001 ). Furthermore, the increase in metastases
`observed with CSA (20 mg/kg/QOD/SQ) was completely prevented by sirolimus
`(p<0.001 ). The dramatic effect of sirohmus was also evident in the immunocompetent
`BALB/c mice. Tacrolimus (p<0.00 I) as well a• CSA (p<0.00 I) increased the number
`of pulmonary renal cancer cell metastases, and sirohmus (p<0.001) prevented
`metastases in the BALB/c mice as it did in the SCIO-beige mice. Strolimus (p<0.01)
`also prevented pulmonary metastasis m the CSA-treated BALB/c mice and in the
`highly malignant mtrarenal cancer model. Survival experiments showed prolongation
`following sirolimus treatment of tumor-inoculated SCIO-beige mice (p<0.01) or
`BALB/c mice (p<0.01). Studies to explore mechanisms for the salutory effects of
`sirolimus showed: I) a reversal of the mvasive phenotype of renal cancer cells
`(ascertained by scanmng electron microscopy); 2) reduction in cell-division
`(determined by flow cytometric analysis of CFSE-loaded cancer cells); and 3)
`promotion of apoptosis (enumerated by flow cytometry). Our studies demonstrate
`that sirolimus ha• a diametrically opposite effect to that of calcineurin inhibitors on
`tumor progression. The unlinking of immunosuppression needed for allograft
`protection from mechanisms constrammg neoplasta progressmn opens new avenues
`for the prevention and/or management of post-transplant neoplasta.
`
`Abstract#429
`AND
`NEORAL•
`FTY720
`COMBINED WITH
`CORTICOSTEROIDS
`IS EFFECTIVE AND SAFE
`IN
`PREVENTION OF ACUTE REJECTION IN RENAL ALLOGRAFT
`RECIPIENTS (INTERIM DATA). Helio Tedesco,' Barry Kahan, 2
`Georges Mourad;' Yves Vanrenterghem.' Josep Grinyo, 5 Willem
`Weimar,• Pascale Pellet,' Lawrence Chodoff,' Tomasz Sablinski.'
`'Hospital do Rim e da Hipertensao. Sao Paolo, Brazil; 2Univ of
`Texas, Houston; 3Hopital Lapeyronie, Montpe/lier, France; 4U. Z.
`Gasthuisberg, Leuven, Belgium; 'Hospital Ciudad Sanitaria de Bellvitge,
`Barcelona, Spain; 0Academisch Ziekenhuis Rotterdam, Rotterdam, The
`Netherlands; 'Novartis Pharma AG, Basel, Switzerland; "Novartis
`Pharmaceuticals Corp, East Hanover.
`FTY720 is a potent 1mmunomodulator with umque effects on lymphocyte homing.
`Ml:1hlH!s· Multicenter, randomized, open-label dose findmg study to evaluate safety,
`tolerability and preliminary efficacy of FTY720 vs. mycophenolate mofetil (MMF)
`with Neoral~ and corticosteroids (CS) m de novo renal transplantation. Adults aged
`18-65 undergoing primary cadaver or living donor (non-HLA identical) renal
`transplantation, who exhibited good allograft function during the first 12 hours
`post-transplant, were randomized to one of four regimens of FTY720 (loadtng dose
`[LD] on Day I, followed by a once daily maintenance dose), or to MMF 2 gm/day. All
`patients received concurrent Neoral + CS per center standard. Induction with
`antilymphocyte antibodies (Ab) or anti-IL-2Ra Ab was not allowed. B.wllts. 209
`patients were enrolled, and prelimmary efficacy data are available for 159 patients
`who completed at least 30 days on study.
`Treatment•
`Num~..- ('Jti) Blops,~connrmcd Acute RtJtttion
`FTY720 lmg LD + O Hmg QD
`8/l9 (20 5'.f)
`I VH 05 I% J
`FTY720 2mg LD + 0 5mg QD
`FTY720 4mg LO + I Omg QD
`4/20 {20 0% l
`FfY720 4mg LD + 2 '.'img QD
`1/28 (1 6%)
`MMF 2 gm/day
`'i/l"i ( 14 1'k)
`sm1I FTY720 was well tolerated. Episodes of transient bradycardia without
`symptoms or sequelae, most of which occurred within firs1 24h post-transplant, were
`reported in 1 l /124 (8. 9%) of FTY720-treated patients vs. 2/35 (5.7%) of MMF-treated
`patients. Graft survival 1s 99% (one graft loss in the MMF group) and patient survival
`1s 100%. Copclusjons. Prehminary analysis indicates that FTY720 appears to be
`
`PLENARY: JOINT SESSION
`
`effective in the prevention of acute rejection in de novo renal transplant patients
`when used with Neoral and CS. Additional trials are underway to evaluate the role
`of FTY720 in the prevention of acute rejection and graft loss after renal
`transplantation.
`
`Abstract# 430
`ICOS/B7RP-1 COSTIMULATION IN ACUTE AND CHRONIC
`ALLOGRAFT REJECTION. Engin Ozkaynak, 1 Wei Gao,' Nida
`Shemmeri,' Chi Wang,' Anthony J. Coyle,' Wayne W. Hancock.'
`1Millennium Pharmaceuticals, Inc., Cambridge. MA.
`In vitro data show activation of primary T cells requires CD28/B7 costimulatmn but
`effector T cell functions are CD2&/B7-independent. In addiuon, costlmulation blockade
`with CTLA4-lg or CD 154 mAb causes prolonged graft survival but chronic rejection
`intervenes, ind1catmg add1t1onal costimulatory pathways are active in vivo. We
`present data on the role of inducible costimulatory molecule (ICOS) and its ligand,
`B7RP-1, in transplantatmn (Tx). Serial Northerns showed that whereas normal heart
`lacked !COS mRNA. intragraft expression was detected by 5d and peaked at rejection
`at 7d in unmodified BALB/c->BL/6 mouse cardiac allograft recipients;
`immunohistology with a blocking rat anti-mJCOS mAb (12A&) localized !COS to
`infiltratmg T cells. Therapy with I 2A8, but not an isotype-matched, non-blocking
`rat ant1-mICOS mAb ( \ 5F9), prolonged graft suTV1val (2o±I d vs. 7-Sd, respectively,
`p<0.001), and in ongoing studies, a mICOS-lg fusion protein prolonged survival to
`>I Sd (p<0.01 ). Molecular assays of 7d grafts showed that compared to controls, anti(cid:173)
`ICOS mAb suppressed intragraft expression ofJFN-y, IL-10 and multiple chemokines
`and their receptors. Mice treated with a subtherapeutic course of CsA rejected their
`allografts by IOd, as did mice treated with lgG/low CsA, whereas allografts in
`recipients treated with anti-JCOS mAb/low CsA are currently >60d post-Tx (p<0.001).
`A role for ICOS in chronic rejection wa• also assessed; allografts were performed in
`conjunction with CDl54 mAb (250 µg, i.p. at Tx) plus anti-ICOS or control IgG
`therapy (500 µg/d, bid, i.p., for 14 d), and were harvested at 30d post-Tx. Scoring of
`elastin-stamed allografts (>6/group) showed IgG-treated controls had severe Tx
`artenosclerosis (4.4 ± 0.6, mean± SD) whereas vessels were largely normal post(cid:173)
`ICOS mAb (0.2 ± 0.1, p<0.001 ), and the myocardium was well preserved. In summary.
`we show that (i) ICOS is involved in acute rejection; (ii) targeting ICOS/B7RP-I
`interactions prolongs allograft survival and suppresses intragraft cytokine expression
`and T cell activation; (iii) the beneficial effects of blocking ICOS/B7RP- I
`costimulation are not impaired by concomitant CsA therapy; and (iv) !COS-dependent
`costimulation plays a key role in the development of Tx arteriosclerosis, including
`after interruption of CD40/CDl54 signaling. Hence, our data demonstrate for the first
`time a key role of the ICOS/87RP- l pathway in acute and chronic alloresponses.
`
`Abstract# 431
`TWO-YEAR INSULIN INDEPENDENCE AND METABOLIC
`FOLLOW-UP AFTER ISLET-ALONE TRANSPLANTATION IN
`AUTOIMMUNE DIABETES. A. M.J. Shapiro,' E. A. Ryan,' R. V.
`Rajotte, 1 G. S. Korbutt, 1 T. Kin.' K. O'Kelly.' G. L. Wamock,1 D. L.
`Bigam, 1 N. M. Kneteman, 1 J. R.T. Lakey.' 1Surgery. University of
`Alberta, Edmonton, AB. Canada.
`Purpose: To evaluate longer-term outcomes of islet-alone transplantation in
`autoimmune diabetes.
`Methods: 15 consecutive patients with longstanding Type I diabetes underwent
`islet-alone transplantation with ABO-compatible cadaveric islets infused
`intraportally by percutaneous access. Steroid-free immunosuppression consisted of
`daclizumab inductmn with maintenance sirolimus and low-dose tacrolimus.
`Results· Median follow-up is 17 .6 months (first 7 patients) and 8.5 months overall,
`with the longest patient remainmg off msulin for 21 months currently. All patients
`have sustamed insulin productmn (C-peptide meal: mean 1.99 ± 0.2 pre, rising to
`3. 90 ± 0. 7 ng/ml at 90 min). 12/15 patients are free of insulin currently ( 4 have normal
`glucose tolerance). 2/15 have a stable form of type II diabetes controlled with oral
`hypoglycemic agents and occasional low doses of insulin (<IO units/day), and 1/15
`awaits a second islet infusion. All patients have required more than one pancreas
`donor (mean islet mass 11.437 IEJkg). There have been no episodes of CMV infection
`(mismatches in 8/15 cases). There have been no cases of PTI..D, malignancy or serious
`infection to date. Mean serum creatinine was unchanged pre-transplant vs current
`(I. I pre vs I. I mg/di), although 2 patients with inadequate pre-transplant clearance
`had post-transplant elevation which has improved by withdrawal of tacrolimus and
`replacement with mycophenolate.
`Mean HbAIC was completely corrected by islet transplant (mean 8.9% pre vs 5.6%
`(3 mo). 5. 7% (6 mo) and 5 .6% (12 mo)). IVGTT data indicate that acute insulin response
`(AIRg) was consistently maintained for up to 12 months of available follow-up, with
`no evidence of deterioration in function over time (no acute rejection and no
`autoimmune recurrence). The increment in AIRg was more marked after the subsequent
`transplant than after the ftrst (0.12 ±Q. J mitial vs 2.42±Q.6mU/ml subsequent, p<0.01),
`suggesting that the imtial transplant may have facilitated engraftment of the
`subsequent graft.
`Conclusions· Sustamed long-term independence from insulin can be achieved with
`low risk in patients undergoing 1slet-alone transplantation using a steroid-free
`1mmunosuppress1ve protocol.
`
`243
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 001
`
`

`

`By continuing to browse this site you agree to us using cookies as described in About Cookies
`
`Log in / Register
`
`Go to old article view
`
`TRANSPLANT 2001: The Joint American Transplant Meeting
`
`Explore this journal >
`
`Full publication history
`
`View/save citation
`
`
`First published: May 2001
`DOI: 10.1111/j.1600-6143.2001.tb00014.x
`Check for updates
`
`Cited by (CrossRef): 0 articles
`
`Citation tools
`
`View issue TOC
`Volume 1, Issue S1
`May 2001
`Pages 47–476
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 002
`
`

`

`Continue reading full article
`
`Article Information
`
`DOI
`
`10.1111/j.1600-6143.2001.tb00014.x
`View/save citation
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 003
`
`

`

`Format Available
`
`Full text: PDF
`
`Munksgaard International Publishers Ltd, 2001
`
`Request Permissions
`
`Publication History
`
`Issue online: 25 August 2010
`Version of record online: 25 August 2010
`
`Related content
`
`Articles related to the one you are viewing
`
`Powered by
`Wiley Online Library
`
`Browse Publications
`Browse by Subject
`Resources
`
`Help & Support
`Cookies & Privacy
`Terms & Conditions
`
`About Us
`Wiley Job Network
`Advertisers & Agents
`
`Copyright © 1999 - 2017 John Wiley & Sons, Inc. All Rights Reserved
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 004
`
`

`

`Daniel R. Evans
`
`From:
`Sent:
`To:
`Cc:
`Subject:
`
`Terry Stokke <tlstokke@elfresearch.com>
`Tuesday, June 06, 2017 5:31 PM
`Daniel R. Evans
`Hope Porter
`FW: Case Number: 01984893 Your case 01985192 [ ref:_00Dd0eeku._5000W13jiyb:ref
`]
`
`Here is their response, Dan. 
` 
`Terry 
` 
`From: cs-journals@wiley.com [mailto:cs-journals@wiley.com]
`Sent: Tuesday, June 6, 2017 4:14 PM
`To: tlstokke@elfresearch.com
`Subject: Case Number: 01984893 Your case 01985192 [ ref:_00Dd0eeku._5000W13jiyb:ref ]
`
`Dear Terry Stokke,
`
`
`The American Journal of Transplantation, Supplement 1, Volume 1 (2001)
`
`
`Thank you for your recent communication regarding the above journal article.
`
`According to our records this supplement articles was published as follows:
`
`Publication History
`
` Manuscript Accepted Issue online:25 August 2010
` Early View Version of record online:25 August 2010
` Officially Published to an Volume & Issue May 2001
`
`Kind regards,
`
`Christine Goff
`Journal Customer Services
`
`
`
`
`If you require further assistance with this matter or would like information on any of our other journals please visit Online
`Get Help to assist with many of your queries 24 hours a day, 7 days a week.
`
`-------------- Original Message ---------------
`
`From: Terry Stokke [tlstokke@elfresearch.com]
`Sent: 05/06/2017, 13:19
`To: cs-journals@wiley.com
`Subject: Case Number: 01984893 [Case Number : 01985192]
`{5000W000013jiybQAA.0030W00003KMuFUQA1}
`
`
`1
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 005
`
`

`

`A final revision.
`
`
` 
`
`************
`
`
` 
`
`Hello,
`
` 
`
`I am trying to verify the publication date of a supplement to the American Journal of Transplantation, i.e., The 
`American Journal of Transplantation, Supplement 1, Volume 1 (2001).  
`
`
` 
`
`The Wiley Online Library indicates that it was first published in May, 2001.  
`
` 
`
`I am attaching copies of the Wiley Online web page and the Luan Abstract published in The American Journal 
`of Transplantation, Supplement 1, Volume 1 (2001).  
`
`
` 
`
`Can you please verify for me that The American Journal of Transplantation, Supplement 1, Volume 1 (2001) 
`was published in May of 2001?  
`
`
` 
`
`Thanks.
`
`
` 
`
`Terry Stokke
`
`
` 
`
`Attachments (2):  
`
`(1) Am J Transplant webpage printout.pdf of the Wiley Online Library related to The American Journal of 
`Transplantation, Supplement 1, Volume 1 (2001); see http://onlinelibrary.wiley.com/doi/10.1111/j.1600‐
`6143.2001.tb00014.x/abstract, accessed on May 24, 2017 and 
`
`(2) Am J Transplant Luan Abstract No. 428.pdf a printed abstract page cited as:  Luan et al., Sirolimus Prevents 
`Tumor Progression: mTOR Targeting for the Inhibition of Neoplastic Progression, American Journal of 
`Transplantation, Supplement 1, Volume 1 (2001), Page 243, Abstract No. 428 (“Luan Abstract”).
`
`2
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 006
`
`

`

`TRANSPLANT 2001
`The Joint American Transplant Meeting
`Day-at-a-Glance, Monday, May 14, 2001
`
`6:30 AM - 7:50 AM
`Page 77
`
`Page 77
`
`Page 77
`
`8:00 AM - 9:30 AM
`Page 77
`
`Page 77
`
`Concurrent Sunrise Symposia
`Sunrise Symposium I: New Technologies in
`Transplantation Immunobiology
`Sheraton Chicago Ballroom 4-7, Sheraton
`Sunrise Symposium II: Video Session II:
`Techniques in Expanding the Liver Donor
`Pool
`Chicago Ballroom 8-10, Sheraton
`Sunrise Symposium III: Recurrent Disease
`after Pediatric Transplantation
`Sheraton Ballroom 1-3, Sheraton
`
`Concurrent Symposia
`Basic Science Symposium: Innate Immunity
`Sheraton Ballroom 1-3. Sheraton
`Clinical Science Symposium: Clinical
`Practice Guidelines: The Prevention of
`Medical Complications after Renal
`Transplantation
`Sheraton Chicago Ballroom 4-7, Sheraton
`
`10:00 AM - 12:00 PM
`lO:OOAM
`Page 77
`
`10:30AM
`Page 77
`11:30AM
`Page 77
`
`Joint Session
`State-of-the-Art Lecture
`Potential Applications of Cloning for
`Transplantation
`Sheraton Chicago Ballroom 4-7, Sheraton
`Joint Plenary Session
`Sheraton Chicago Ballroom 4-7, Sheraton
`Award Presentations
`Sheraton Chicago Ballroom 4-7, Sheraton
`
`12:30 PM - 1 :30 PM
`Page78
`
`Parallel Luncheon Workshops
`Sheraton and Intercontinental
`
`12:30 PM - 1 :30 PM
`Page 78
`
`Selected Poster Sessions
`Sheraton
`
`2:00 PM • 3:30 PM
`Page 79
`
`Page 80
`
`Page 81
`
`Page 8I
`
`Concurrent Sessions
`Concurrent Session 21: Basic Science:
`Rejection III
`Chicago Ballroom JO, Sheraton
`Concurrent Session 22: Kidney
`Transplantation: Minimizing
`Immunosuppression
`Chicago Ballroom 617, Sheraton
`Concurrent Session 23: Kidney
`Transplantation: Live-Donors, Factors and
`Outcomes
`Chicago Ballroom 819, Sheraton
`Concurrent Session 24: Basic Science:
`Immunosuppression 11
`Sheraton Ballroom 1-3, Sheraton
`
`Concurrent Session 25: Mechanisms of Acute/
`Chronic Rejection
`Sheraton Ballroom 415, Sheraton
`Concurrent Session 26: T Cells in Ischemia/
`Reperfusion Injury
`Empire Room, Intercontinental
`Concurrent Session 27: Cardiac Allograft
`Rejection: Cell Death and Molecular Markers
`Exchange Room, Intercontinental
`Concurrent Session 28: Living Liver
`Donors I
`Grand Ballroom, Intercontinental
`Concurrent Session 29: Basic Science: Co(cid:173)
`Stimulation
`King Arthur Court Ballroom, Intercontinental
`Concurrent Session 30: Liver Transplantation
`Outcomes
`Renaissance Ballroom, Intercontinental
`
`Concurrent Sessions
`Concurrent Session 31: Regulation of
`Allreactive T Cell Responses
`Chicago Ballroom JO. Sheraton
`Concurrent Session 32: Viral Infections in
`Renal Transplantation
`Chicago Ballroom 617, Sheraton
`Concurrent Session 33: Kidney
`Transplantation: Immunotherapy,
`Economics and Efficacy
`Chicago Ballroom 819, Sheraton
`Concurrent Session 34: Basic Science:
`Tolerance I
`Sheraton Ballroom I-3. Sheraton
`Concurrent Session 35: Antibodies and
`Immunomodulation
`Sheraton Ballroom 415, Sheraton
`Concurrent Session 36: Bone Marrow Cell
`Transplantation
`Empire Room, Intercontinental
`Concurrent Session 37: Cardiac
`Transplantation Complications: Diagnosis
`& Treatment
`Exchange Room, Intercontinental
`Concurrent Session 38: Liver
`Transplantation: Allocation
`Grand Ballroom, Intercontinental
`Concurrent Session 39: Pathology, Techniques
`and Results of Pancreas Transplantation
`King Arthur Court Ballroom, Intercontinental
`Concurrent Session 40: Pediatrics I (Liver)
`Renaissance Ballroom, Intercontinental
`
`Page 82
`
`Page 82
`
`Page 83
`
`Page 83
`
`Page 84
`
`Page 84
`
`4:00 PM • 5:30 PM
`Page 85
`
`Page 85
`
`Page 86
`
`Page 86
`
`Page 87
`
`Page 87
`
`Page 88
`
`Page 88
`
`Page 89
`
`Page 89
`
`75
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 007
`
`

`

`TRANSPLANT 2001
`The Annual American Transplant Meeting
`Day-at-a-Glance, Monday, May 14, 2001 (Continued)
`
`8:00 AM· 7:00 PM
`5:30 PM· 7:00 PM
`
`Page 90
`
`Page 90
`
`Page 91
`
`Page 91
`Page 92
`
`Page 92
`
`Page 93
`
`Page 94
`
`Page 95
`
`Page 95
`Page 96
`
`Page 96
`
`Poster Session II
`Presenters in Attendance
`Beer and Pretzel Receptwn
`River Exhibition Hall, Sheraton
`Kidney· Acute/Chronic Rejection II
`Kidney· GVH, Complications, Infections II
`Kidney - lmmunosuppression B II
`Kidney - lmmunosuppression A II
`Kidney· Pediatrics, Recurrent Disease II
`Kidney· Preservation, Donation/ Allocation,
`Economics/Public Policy, Surgical Techniques,
`andOtherD
`Liver - lmmunosuppression, Acute/Chronic
`Rejection, GVH, Pediatrics
`Liver· Infections, Complications, Recurrent
`Disease, Surgical Techniques II
`Liver· Preservation, Economics/Public Policy,
`Donation Allocation, Other II
`Pancreas and Islets· All Topics II
`Heart/Lung· All Topics II
`Bone Marrow - All Topics II
`
`Page 97
`Page 97
`Page 98
`
`Page 99
`
`Page 99
`
`Page JOO
`
`Page JOO
`
`Page JOI
`
`lmmunosuppression, Preclinical Studies II
`ToleranceD
`Acute/Chronic Rejection II
`Allorecognition, Antigen Presentation, Co(cid:173)
`stimulation and Other II
`Lymphocyte Activation, Lymphocyte-Down·
`Regulation, Chemokines, Adhesion Molcules
`and Cytokines II
`Genetic Modulation, Islet/Cell Transplantation
`and Booe Marrow/GVll 0
`Tissue Injury, Preservation II
`Xenotransplantation II
`
`5:45PM
`Page 89
`
`ASTS Business Meeting
`Sheraton Ballroom 1-3, Sheraton
`
`76
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 008
`
`

`

`Clinical Science Symposium: Clinical Practice
`Guidelines: The Prevention of Medical Complications
`after Renal Transplantation
`
`Chairs: Bertram Kasiske and Gabriel Danovitch
`
`8:00 AM
`
`8:15 AM
`
`9:00 AM
`
`9: 15 AM
`
`Post-transplant follow-up: How frequent, how thorough and
`by whom?
`
`Gabriel Donovitch
`Evidence that post-transplant cardiovascular disease can be
`prevented
`
`Bertram Kasiske
`How should post-transplant bone disease be diagnosed and
`treated?
`
`Margaret Bia
`Cancer: Post-transplant screening and prevention
`Connie Davis
`
`9:30 AM
`
`Break
`
`Joint Plenary Session
`10:00 AM • 12:00 PM
`
`Sheraton Chicago Ballroom 4-7, Sheraton
`Chairs: Mohamed Sayegh and Nancy Ascher
`
`10:00AM
`
`State-of-the-Art Lecture
`Potential Applications of Cloning for
`Transplantation
`Alan Colman
`
`10:30 AM SIROLIMUS PREVENfS TIJMOR PROGRESSION:
`mTORTARGETING FOR TllEINIDBffiON OF
`NEOPLASTIC PROGRESSION. (Abstract #428) Young
`Investigators Award
`Fulung Luan, Mary Maluccio, Vi jay K. Shanna, Minoru
`Hojo. Milagros Lagman, Manikkam Suthanthiran. New York,
`NY; New York, NY.
`10:45 AM FI'Y720COMBINEDWITHNEORALll> AND
`CORTICOSTEROIDS IS EFFECTIVE AND SAFE IN
`PREVENTION OF ACUfERruECTIONINRENAL
`ALLOGRAFTRECIPIENTS(Jll,TERIMDATA).(A~
`#429)
`Helio Tedesco, Barry Kahan, Georges Mourad, Yves
`Vanrenterghem, Josep Grinyo, Willem Weimar. Pascale
`Pellet, Lawrence Chodoff, Tomasz Sablinski. Sao Paolo,
`Brazil; Houston; Montpellier, France; Leuven, Belgium;
`Barcelona, Spain; Rotterdam, The Netherlands; Basel,
`Switzerland; East Hanover.
`ICOS/B7RP-1 COSTIMULATION IN ACUTE AND
`CHRONIC ALLOGRAFTREJECTION. (Abstract#430)
`Young Investigators Award
`Engin Ozkaynak, Wei Gao, Nida Shemmeri, Chi Wang,
`Anthony J. Coyle, Wayne W. Hancock. Cambridge, MA.
`11:15 AM 1WO-YEARINSULININDEPF..l\'DENCEAND
`METABOLIC FOLLOW-UP AFTER ISLET-ALONE
`TRANSPLANTATION IN AUIDIMMUNEDIABETES.
`(Abstract #431)
`A. M.J. Shapiro, E. A. Ryan, R. V. Rajotte, G. S. Korbutt, T.
`Kin, K. O'Kelly, G. L. Warnock, D. L. Bigam, N. M.
`Kneteman, J. R.T. Lakey. Edmonton, AB, Canada.
`
`11:00 AM
`
`11:30 AM Award Presentations
`
`Monday, May 14, 2001
`
`Concurrent Sunrise Symposium
`6:30 AM· 7:45 AM
`
`Sunrise Symposium I: New Technologies In
`Transplantation Immunology
`
`Sheraton Chicago Ballroom 4-7, Sheraton
`Chair: Abraham Shaked
`
`6:30 AM
`
`The latest vectors for gene therapy
`Abraham Shaked
`
`6:55 AM
`
`Bioinformatics
`Isaac Kohane
`
`7:20 AM
`
`Analyzing the T cell repertoire by landscape spectratyping
`Jean-Paul Sou/illou
`
`Sunrise Symposium II: Video Session II: Techniques In
`Expanding the Liver Donor Pool
`
`Chicago Ballroom 8-10, Sheraton
`Chair: Thomas Heffron
`
`6:30 AM
`
`6:55 AM
`
`7:20 AM
`
`Current refinements in living donor left lateral
`segmentectomy
`Thomas Heffron
`Living donor right lobectomy
`Charles Miller
`In-situ cadaver donor split liver procurement
`Hasan Yersiz
`
`Sunrise Symposium Ill: Recurrent Disease after
`Pediatric Transplantation
`
`Sheraton Ballroom 1-3, Sheraton
`Chair: Steven Webber
`
`6:45 AM
`
`6:30AM GeneticsofFSGS
`Martin Pollak
`Recurrent glomerular disease
`Mark Denton
`Recurrent liver disease in children
`Sue McDiarmid
`Recurrent disease after heart and lung transplantation
`Steven Webber
`
`7:00 AM
`
`7:15 AM
`
`Concurrent Symposia
`8:00 AM • 9:30 AM
`
`Basic Science Symposium: Innate Immunity
`
`Sheraton Ballroom 1-3, Sheraton
`Chairs: Angus Thomson and David Perkins
`
`8:00 AM
`
`8:30 AM
`
`9:30 AM
`
`Innate immunity: From plants to humans
`Albert Bende/ac
`CD14-dependent clearance of apoptotic cells. A link
`between an innate and adaptive immunity
`Christopher Gregory
`Toll-like receptors and regulation of adaptive immune
`responses
`
`Rusian Medzhitov
`
`n
`
`West-Ward Exhibit 1005
`Luan 2001
`Page 009
`
`